The aspires study: activating cancer survivors and their primary care providers to increase colorectal cancer screening

Ended Project Grant Awarded Last action

Award ID
R01CA255269
Recipient
Awarding agency
Obligated
$7,412,059

Award facts

Assistance listing
93.393 Cancer Cause and Prevention Research
Completion date
Funding
  • $6,663,835.00 Federal
  • $748,224.00 Non-federal
Place of performance
Chicago, IL 60637, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Childhood cancer survivors treated with abdominal or pelvic radiotherapy (RT) are almost four times more likely to develop colorectal cancer (CRC) compared to the general population with their elevated risk evident by the age of 30 years with no plateau. Since earlier detection of precancerous lesions (i.e. adenomas) or CRC is strongly associated with improved survival, screening with colonoscopy or multitarget stool DNA testing (MT- sdna) with a colonoscopy after a positive test is recommended starting at age 30. Unfortunately, the vast majority of survivors at high-risk for CRC are not adherent to recommended screening. Magnifying this problem, most childhood cancer survivors are no longer followed at a cancer center, are unaware of their risks and are being followed by primary care providers (PCPS) who are not informed about the recommended follow-up care. In order to improve adherence to CRC screening guidelines in high-risk childhood cancer survivors, we propose the aspires (activating cancer survivors and their primary care providers to increase colorectal cancer screening) study, which is the first known intervention to attempt to increase CRC screening rates in this population using a remote digital mhealth intervention. This is a 3-arm randomized controlled trial to evaluate the utility of patient activation with and without added PCP activation to increase CRC screening. We propose to randomize 315 survivors, who are at least 30 years of age, with a history of abdominal or pelvic radiation for a childhood cancer and without a history of CRC. The primary outcome is obtaining CRC screening with colonoscopy or MT-sdna during the 12-month study period. We will determine the comparative effectiveness of (1) a mhealth patient activation intervention and (2) patient activation plus PCP activation, compared to control. Secondary aims include (1) conducting a multi-stakeholder mixed-methods consolidated framework for implementation research (CFIR)-informed evaluation to understand patient, provider and system factors associated with uptake of the intervention, to explore enablers and barriers to uptake of CRC screening, and to generate recommendations for future adaptation, scalability and sustainability; (2) identify potential moderators and mediators of uptake of CRC screening; and (2) estimate the cost-effectiveness of the intervention. The proposed aspires study brings together a research team with necessary expertise and experience in survivorship, CRC screening, dissemination and implementation, and mhealth intervention research with the unique resource of the 31-institution childhood cancer survivor study (CCSS). Notably, the CCSS represents the single largest cohort of survivors in the target population and the infrastructure to conduct the proposed study. Results from this intervention will have important implications for patients at high-risk for CRC and we expect that findings from this study will provide the evidence for implementation and dissemination of our CRC screening interventions targeting these populations.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $567,763 $0
Amendment $567,763 $0
Amendment -$567,763 $0
Amendment -$567,763 $0
Amendment -$567,763 $0
Amendment $606,991 $0
Amendment $34,377 $0
Amendment $34,377 $0
Amendment $618,795 $0
Amendment $618,795 $0
Amendment $618,795 $0
Amendment $633,206 $0
Amendment $633,206 $0
Amendment $633,206 $0
Amendment $53,203 $0
Amendment $53,203 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $598,498 $0
Amendment $0 $0
Amendment $598,498 $0
Amendment $6,687 $0
Amendment $6,687 $6,687
Amendment $741,537 $0
Original award $741,537 $741,537
Show all 29

Subawards

Subrecipient Amount Awarded
ST. Jude Children's Research Hospital Dr. Gregory Armstrong is the PI of CCSS and will assume the role of onsite PI and be responsible for the oversight of the CCSS Coordinating Center activities.… $141,266
The Pennsylvania State University Dr. Kim will serve as an mPI where she will have oversight over the aims of the grant, including communication, strategy, evaluation and dissemination of… $64,502

Quick answers

Who received award R01CA255269?

R01CA255269 was awarded to The University Of Chicago by National Cancer Institute (National Institutes of Health) on March 1, 2021.

How much is award R01CA255269 worth?

$7,412,059 has been obligated on R01CA255269: $6,663,835 in federal funding and $748,224 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login